WO1993009778A2 - Utilisation de brl 38227 pour le traitement et la prophylaxie de l'hyperlipidemie - Google Patents
Utilisation de brl 38227 pour le traitement et la prophylaxie de l'hyperlipidemie Download PDFInfo
- Publication number
- WO1993009778A2 WO1993009778A2 PCT/GB1992/002141 GB9202141W WO9309778A2 WO 1993009778 A2 WO1993009778 A2 WO 1993009778A2 GB 9202141 W GB9202141 W GB 9202141W WO 9309778 A2 WO9309778 A2 WO 9309778A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hyperlipidemia
- treatment
- prophylaxis
- brl
- pharmaceutically acceptable
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 22
- 208000031226 Hyperlipidaemia Diseases 0.000 title claims abstract description 19
- 238000011321 prophylaxis Methods 0.000 title claims abstract description 18
- TVZCRIROJQEVOT-CABCVRRESA-N Cromakalim Chemical compound N1([C@@H]2C3=CC(=CC=C3OC([C@H]2O)(C)C)C#N)CCCC1=O TVZCRIROJQEVOT-CABCVRRESA-N 0.000 claims abstract description 23
- 238000000034 method Methods 0.000 claims abstract description 11
- 241000124008 Mammalia Species 0.000 claims abstract description 7
- 230000000069 prophylactic effect Effects 0.000 claims abstract description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 12
- 150000002632 lipids Chemical class 0.000 claims description 10
- 239000002876 beta blocker Substances 0.000 claims description 8
- 229940097320 beta blocking agent Drugs 0.000 claims description 8
- 206010020772 Hypertension Diseases 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- 235000012000 cholesterol Nutrition 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 102000007330 LDL Lipoproteins Human genes 0.000 claims description 5
- 108010007622 LDL Lipoproteins Proteins 0.000 claims description 5
- 239000002934 diuretic Substances 0.000 claims description 5
- 150000003626 triacylglycerols Chemical class 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims 3
- 239000000203 mixture Substances 0.000 description 14
- 150000001875 compounds Chemical class 0.000 description 8
- 239000003981 vehicle Substances 0.000 description 7
- 239000003826 tablet Substances 0.000 description 4
- 102000015779 HDL Lipoproteins Human genes 0.000 description 3
- 108010010234 HDL Lipoproteins Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000011863 diuretic therapy Methods 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 229940030606 diuretics Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000004036 potassium channel stimulating agent Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
Definitions
- the present invention relates to a method for the treatment and/or prophylaxis of hyperlipidemia.
- EP-A-120428 (Beecham Group p.l.c.) describes the potassium channel activator, BRL 38227 and its use as an antihypertensive agent.
- BRL 38227 lowers the level of plasma lipids such as triglycerides and cholesterol. As such, this compound is of value in the treatment of hyperlipidemia, and is especially useful in the lowering of lipid levels in hypertensive patients. It is also known that certain classes of compound tend to be associated with increasing lipid levels in patients, such as ⁇ -blockers or diuretics, thus, BRL 38227 in combination with ⁇ -blockers and/or diuretics has the potential of counteracting the lipid raising effects of these agents.
- the present invention provides a method for the treatment and/or prophylaxis of hyperlipidemia especially that associated with ⁇ - blockers or diuretic therapy in mammals, such as humans, especially those also suffering from hypertension (which is concomitantly treated), which method comprises administering to the mammal in need of such treatment and/or prophylaxis an effective and/or prophylactic amount of BRL 38227, or a pharmaceutically acceptable salt thereof.
- BRL 38227 is suitable for specifically reducing the percentage of low density lipoproteins (LDL) in patients as well as the percentage of triglycerides and cholesterol which are the lipids associated with artery hardening. The reduction of such lipids is believed to be of benefit to the patient.
- LDL low density lipoproteins
- HDL high density lipoproteins
- BRL 38227 is the (-)-enantiomer of the compound of Example 1 of EP-A- 76075 and United States Patent No. 4446113, ( ⁇ )-6-cyano-3,4-dihydro-2,2- dimethyl-trans-4-(2-oxo- 1- pyrrolidinyl)-2H-benzo[b]pyran-3-ol.
- Examples of pharmaceutically acceptable salts are as described in the aforementioned European Patent references, the subject matter of which are incorporated herein by reference.
- references to BRL 38227 include solvates such as hydrates.
- BRL 38227 may be prepared as described in the aforementioned Patent Publications/References, or as described in EP-A-385584 (Beecham Group p.l. ⁇ ).
- BRL 38227 is in substantially pure pharmaceutically acceptable form.
- the administration of the compound may be by way of oral, sublingual, transdermal or parenteral administration.
- a unit dose will normally contain 0.1 to 50 mgfor example 0.5 to 10 mg, of BRL 38227.
- Unit doses will normally be administered once or more than once a day, for example 2, 3, or 4 times a day, more usually 1 to 3 times a day, such that the total daily dose is normally in the range, for a 70 kg adult of 0.1 to 50 mg, for example 0.5 to 10 mg, that is in the range of approximately 0.001 to 1 mg/kg/day, more usually 0.005 to 0.2 mg/kg/day.
- BRL 38227 is administered in the form of a unit-dose composition, such as a unit dose oral or parenteral composition.
- compositions are prepared by admixture and are suitably adapted for oral or parenteral aoministration, and as such may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, injectable and infusable solutions or suspensions or suppositories.
- Orally administrable compositions are preferred, in particular shaped oral compositions, since they are more convenient for general use.
- Tablets and capsules for oral administration are usually presented in a unit dose, and contain conventional excipients such as binding agents, fillers, d luents, tabletting agents, lubricants, disintegrants, colourants, 5 flavourings, and wetting agents.
- the tablets may be coated according to well known methods in the art.
- Suitable fillers for use include cellulose, mannitol, lactose and other similar agents.
- Suitable disintegrants include starch, 10 polyvinylpyrrolidone and starch derivatives such as sodium starch glycollate.
- Suitable lubricants include, for example, magnesium stearate.
- Suitable pharmaceutically acceptable wetting agents include sodium lauryl sulphate.
- compositions may be prepared by conventional methods of blending, filling or tabletting. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are, of course, conventional in the art.
- Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use.
- Such liquid preparations may contain conventional
- additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example, almond oil, fractionated
- coconut oil oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents.
- Oral formulations also include conventional sustained release formulations, such as tablets or granules having an enteric coating.
- fluid unit dose forms are prepared containing the potassium channel activator and a sterile vehicle.
- the compound depending on the vehicle and the concentration, can be either suspended or dissolved.
- Parenteral solutions are normally prepared by dissolving the compound in a vehicle and filter sterilising before filling into a suitable vial or ampoule and sealing.
- adjuvants such as a local anaesthetic, preservatives and buffering agents are also dissolved in the vehicle.
- the composition can be frozen after filling into the vial and the water removed under vacuum.
- Parenteral suspensions are prepared in substantially the same manner except that the compound is suspended in the vehicle instead of being dissolved and sterilised by exposure to ethylene oxide before suspending in the sterile vehicle.
- a surfactant or wetting agent is included in the composition to facilitate uniform, distribution of the compound.
- formulations suitable for topical use may be employed, optionally containing penetration enhancers.
- compositions will usually be accompanied by written or printed directions for use in the treatment concerned.
- the present invention also provides the use of BRL 38227, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment and/or prophylaxis of hyperlipidemia especially that associated with ⁇ -blockers or diuretic therapy .
- Such treatment and/or prophylaxis may be carried out as hereinbefore described.
- the above use of BRL 38227 is especially beneficial to patients also suffering from hypertension, (which is concomitantly treated).
- the present invention further provides a pharmaceutical composition for use in the treatment and/or prophylaxis of hyperlipidemia especially that associated with ⁇ -blockers or diuretic therapy which comprises BRL 38227 or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.
- a pharmaceutical composition for use in the treatment and/or prophylaxis of hyperlipidemia especially that associated with ⁇ -blockers or diuretic therapy which comprises BRL 38227 or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.
- the above pharmaceutical composition is especially beneficial to patients also suffering from hypertension, (which is concomitantly treated).
- compositions may be prepared in the manner as hereinbefore described.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Procédé de traitement et/ou de prophylaxie de l'hyperlipidémie chez les mammifières, dans lequel on administre au mammifère nécessitant ce type de traitement et/ou de prophylaxie, une quantité efficace et/ou prophylactique de BRL 38227.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9124754.4 | 1991-11-21 | ||
GB919124754A GB9124754D0 (en) | 1991-11-21 | 1991-11-21 | Pharmaceuticals |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1993009778A2 true WO1993009778A2 (fr) | 1993-05-27 |
WO1993009778A3 WO1993009778A3 (fr) | 1993-07-22 |
Family
ID=10705002
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1992/002141 WO1993009778A2 (fr) | 1991-11-21 | 1992-11-19 | Utilisation de brl 38227 pour le traitement et la prophylaxie de l'hyperlipidemie |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU2949592A (fr) |
GB (1) | GB9124754D0 (fr) |
WO (1) | WO1993009778A2 (fr) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8800199D0 (en) * | 1988-01-06 | 1988-02-10 | Beecham Group Plc | Pharmaceutical preparation |
GB8927980D0 (en) * | 1989-12-11 | 1990-02-14 | Beecham Group Plc | Pharmaceuticals |
-
1991
- 1991-11-21 GB GB919124754A patent/GB9124754D0/en active Pending
-
1992
- 1992-11-19 WO PCT/GB1992/002141 patent/WO1993009778A2/fr active Application Filing
- 1992-11-19 AU AU29495/92A patent/AU2949592A/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2949592A (en) | 1993-06-15 |
GB9124754D0 (en) | 1992-01-15 |
WO1993009778A3 (fr) | 1993-07-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0820288B1 (fr) | Utilisation de dextromethorphane ou de dextrorphane pour le traitement de l'incontinence urinaire | |
EP0173848B1 (fr) | Composés benzopyranniques pour utilisation dans le système cardio-vasculaire | |
US5521168A (en) | Estrogen metabolites for lowering intraocular pressure | |
EP0651642A1 (fr) | Utilisation de 1,3-dicyclopropymethyl-8-amino-xanthine pour le traitement et la prevention du diabete sucre de type ii et de l'obesite | |
EP0323745B1 (fr) | Préparations pharmaceutiques | |
EP0176689B1 (fr) | Composés benzopyranniques pour le traitement de la contraction des muscles lisses | |
US5554610A (en) | Inhalational treatment of pulmonary hypertension and related conditions | |
CA2126354C (fr) | Utilisation de modulateurs de 5-ht4 pour la fabrication d'un medicament pour le traitement des maladies de la vessie | |
WO1992000103A1 (fr) | Preparations pharmaceutiques | |
EP0345948B1 (fr) | Utilisation de 5-HT1A agonistes pour l'obtention d'un médicament protégeant contre les conséquences d'une attaque ischémique | |
US5032596A (en) | Treatment of disorders associated with pulmonary hypertension and/or right heart failure | |
JPH02160720A (ja) | 医薬組成物 | |
SK11902002A3 (sk) | Použitie exemestanu na prípravu liečiva | |
WO1993009778A2 (fr) | Utilisation de brl 38227 pour le traitement et la prophylaxie de l'hyperlipidemie | |
US5162375A (en) | Treatment of neuronal degeneration with 5HT1A agonists | |
EP0271271B1 (fr) | Préparations pharmaceutiques | |
WO2001012265A1 (fr) | Utilisation de la cyamemazine dans le traitement du sevrage brutal aux benzodiazepines | |
US6750195B2 (en) | Use of 5-HT4 modulators for the manufacture of a medicament for the treatment of the bladder diseases | |
JP2002515047A (ja) | 新規方法 | |
EP0214743B1 (fr) | Utilisation de dérivés de la quinoline pour la fabrication de médicaments pour le traitement des maladies cérébrovasculaires et de la sénilité cérébrale | |
EP0372998A2 (fr) | Utilisation des dérivés de benzopyranne pour le traitement de l'épilepsie | |
IE904460A1 (en) | Pharmaceuticals | |
HUP0103149A2 (hu) | Gyógyszerkészítmény Alzheimer-kór kezelésére | |
CA2213842C (fr) | Utilisation de dextromethorphane ou de dextrorpharne pour le traitement de l'incontinence urinaire | |
EP0419135A2 (fr) | Utilisation de la 1,3-di-n-Butyl-7-(2-oxopropyl)xanthine pour le traitement des troubles résultant de l'ischémie cérébrale |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU CA JP KR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL SE |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AU CA JP KR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL SE |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
122 | Ep: pct application non-entry in european phase |